Display options
Cite
Ono M, Ito T, Kanai T, et al. Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer. Onco Targets Ther. 2013;6:1393-8doi: 10.2147/OTT.S51164.
Ono, M., Ito, T., Kanai, T., Murayama, K., Koyama, H., Maeno, K., Mochizuki, Y., Iesato, A., Hanamura, T., Okada, T., Watanabe, T., & Ito, K. (2013). Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer. OncoTargets and therapy, 61393-8. https://doi.org/10.2147/OTT.S51164
Ono, Mayu, et al. "Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer." OncoTargets and therapy vol. 6 (2013): 1393-8. doi: https://doi.org/10.2147/OTT.S51164
Ono M, Ito T, Kanai T, Murayama K, Koyama H, Maeno K, Mochizuki Y, Iesato A, Hanamura T, Okada T, Watanabe T, Ito K. Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer. Onco Targets Ther. 2013 Oct 07;6:1393-8. doi: 10.2147/OTT.S51164. eCollection 2013. PMID: 24124381; PMCID: PMC3794845.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2013 Oct 07;6:1393-8. doi: 10.2147/OTT.S51164. eCollection 2013.

Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer.

OncoTargets and therapy

Mayu Ono, Tokiko Ito, Toshiharu Kanai, Koichi Murayama, Hiroshi Koyama, Kazuma Maeno, Yasuhiro Mochizuki, Asumi Iesato, Toru Hanamura, Toshihiro Okada, Takayuki Watanabe, Ken-Ichi Ito

Affiliations

  1. Division of Breast and Endocrine Surgery, Department of Surgery (II), Shinshu University School of Medicine, Matsumoto, Japan.

PMID: 24124381 PMCID: PMC3794845 DOI: 10.2147/OTT.S51164

Abstract

Bevacizumab when combined with chemotherapy exerts significant activity against many solid tumors through tumor angiogenesis inhibition; however, it can induce severe side effects. We report the rare case of a 27-year-old premenopausal woman with locally advanced breast cancer that was marked by rapid tumor necrosis followed by massive hemorrhage shortly after bevacizumab and paclitaxel administration. On the basis of histopathological examination of a biopsy specimen and computed tomography findings, she was diagnosed with stage IV estrogen and progesterone receptor-negative and human epidermal growth factor receptor type 2-positive breast cancer with multiple organ metastases when she had entered gestational week 24. Cyclophosphamide, Adriamycin®, fluorouracil therapy was initiated, but multiple liver metastases continued to progress. A healthy fetus was delivered by induced delivery and trastuzumab-based treatment was initiated. Although the multiple liver metastases were controlled successfully by trastuzumab combined with paclitaxel, the primary tumor continued to expand even after subsequent administration of three other treatment regimens including anti-human epidermal growth factor receptor type 2 agents and cytotoxic drugs. To inhibit primary tumor growth, a combination therapy with paclitaxel and bevacizumab was subsequently initiated. Following therapy initiation, however, the large tumor occupying the patient's entire left breast became necrotic and ulcerated rapidly. Furthermore, massive hemorrhage from the tumor occurred 5 weeks after bevacizumab-based therapy initiation. Although hemostasis was achieved by manual compression, the patient required blood transfusion for the massive blood loss. She eventually succumbed to respiratory failure. This case report demonstrates that primary breast cancer lesions with skin involvement have the potential to cause massive hemorrhage after bevacizumab-based treatment.

Keywords: adverse event; bevacizumab; breast cancer; hemorrhage; necrosis; paclitaxel

References

  1. N Engl J Med. 2004 Jun 3;350(23):2335-42 - PubMed
  2. Clin Cancer Res. 2007 Apr 1;13(7):1961-70 - PubMed
  3. Oncologist. 2006 Nov-Dec;11(10):1070-1 - PubMed
  4. J Exp Clin Cancer Res. 2011 May 12;30:54 - PubMed
  5. J Wound Care. 2011 Sep;20(9):403-4, 406, 408 passim - PubMed
  6. J Clin Oncol. 2004 Jun 1;22(11):2184-91 - PubMed
  7. J Clin Oncol. 2003 Jan 1;21(1):60-5 - PubMed
  8. Br J Cancer. 2010 Sep 7;103(6):772-5 - PubMed
  9. J Clin Oncol. 2006 Jul 20;24(21):3354-60 - PubMed
  10. Lancet Oncol. 2012 Apr;13(4):375-84 - PubMed
  11. Curr Treat Options Oncol. 2007 Feb;8(1):15-27 - PubMed
  12. N Engl J Med. 2003 Jul 31;349(5):427-34 - PubMed
  13. J Clin Oncol. 2013 May 10;31(14):1719-25 - PubMed
  14. Aesthetic Plast Surg. 2010 Dec;34(6):796-7 - PubMed
  15. J Natl Cancer Inst. 2007 Aug 15;99(16):1232-9 - PubMed
  16. Ann Oncol. 2008 Nov;19(11):1977-8 - PubMed

Publication Types